| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = -$2,126,906 ) |
| | 2021 | 2020 | ADYNXX SUB, INC. | 44 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 001 | 2 | NIH | 8/23/2021 | -$1,524,390 |
| | 2021 | 2020 | ADYNXX SUB, INC. | 44 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 000 | 2 | NIH | 12/10/2020 | $0 |
| | 2021 | 2019 | ADYNXX SUB, INC. | 44 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R43NS113726 | Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain | 000 | 1 | NIH | 8/10/2021 | -$602,516 |
|
| Issue Date FY: 2020 ( Subtotal = $2,858,544 ) |
| | 2020 | 2020 | ADYNXX SUB, INC. | 44 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 002 | 2 | NIH | 9/8/2020 | $2,858,544 |
| | 2020 | 2020 | ADYNXX, INC. | 100 PINE ST STE 500 | SAN FRANCISCO | CA | 94111-5103 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 001 | 2 | NIH | 2/10/2020 | $285,854 |
| | 2020 | 2020 | ADYNXX, INC. | 100 PINE ST STE 500 | SAN FRANCISCO | CA | 94111-5103 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 000 | 2 | NIH | 12/12/2019 | $2,572,690 |
| | 2020 | 2020 | ADYNXX SUB, INC. | 44 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 002 | 2 | NIH | 9/8/2020 | -$2,858,544 |
|
| Issue Date FY: 2019 ( Subtotal = $3,461,060 ) |
| | 2019 | 2019 | ADYNXX, INC. | 100 PINE ST STE 500 | SAN FRANCISCO | CA | 94111-5103 | SAN FRANCISCO | USA | UG3DA048375 | The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate | 000 | 1 | NIH | 12/7/2018 | $2,858,544 |
| | 2019 | 2019 | ADYNXX, INC. | 100 PINE ST STE 500 | SAN FRANCISCO | CA | 94111-5103 | SAN FRANCISCO | USA | R43NS113726 | Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain | 000 | 1 | NIH | 9/23/2019 | $602,516 |
|
|
